Super Session 3

Novel Vaccine Technologies and their Impact on Healthcare

20 April 2021

15:45 - 17:00
Novel Vaccine Technologies and their Impact on Healthcare

Super Session 3

15:45 - 17:00

New vaccines and novel vaccine technologies are in the center of public debate as a consequence of the corona virus pandemic and our industry’s ability to rapidly deliver to society. Since long, vaccines have played an important role in disease prevention, primarily in the area of infectious diseases. Vaccines are here to stay and novel technologies facilitate rapid vaccine development but also open up for curative approaches in other therapeutic areas such as oncology and CNS-disease. This session will deal with the rapid development of novel vaccine technologies, regulatory aspects and promises for new therapeutic vaccines to cure diseases in non-traditional therapeutic areas.

Sponsored by:

MSD

MSD

ProPharma Group

ProPharma Group

Speaker(s):

Dr. Renske Hesselink - Senior Consultant Development and Manufacturing, ProPharma Group
Dr. Michel de Baar - Executive Director, BD&L, Infectious and Cardiometabolic Diseases, Vaccines & Immunology, MSD
Mr. Nils Carlin - Director Research & Development, Etvax
Prof. Seppo Ylä-Herttuala - Professor, University of Eastern Finland
Dr. Frank Follmann - Director, Vaccine Research, Statens Serum Institut
Mr. Göran Conradson - Managing Director, Ziccum

full program